Cargando…
Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer
SIMPLE SUMMARY: Safety and pre-existing or acquired resistance to treatments limit the clinical benefit of most drugs against breast cancer. Great effort has been made to mitigate the limitations of combined drug treatment. We here explored the effect of the combination of ribitol, a sugar metabolit...
Autores principales: | Doddapaneni, Ravi, Tucker, Jason D., Lu, Pei J., Lu, Qi L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486979/ https://www.ncbi.nlm.nih.gov/pubmed/37686632 http://dx.doi.org/10.3390/cancers15174356 |
Ejemplares similares
-
Ribitol alters multiple metabolic pathways of central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics profiling of breast cancer
por: Tucker, Jason Driver, et al.
Publicado: (2022) -
Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer
por: Mustafi, Sushmita, et al.
Publicado: (2019) -
Ribitol enhances matriglycan of α-dystroglycan in breast cancer cells without affecting cell growth
por: Lu, Pei J., et al.
Publicado: (2020) -
ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan
por: Gerin, Isabelle, et al.
Publicado: (2016) -
Ribitol in Solution Is an Equilibrium of Asymmetric Conformations
por: Ohno, Shiho, et al.
Publicado: (2021)